ChayimTech builds the measurement-and-modulation platform for cellular aging — chromosome-resolved biological-age sensing on long-read sequencing, paired with transient mRNA signaling. Plus elite R&D services through ChayimTech Labs.
It is the root driver of degenerative disease, spiraling healthcare cost and declining biological productivity — yet there is no programmable, scalable infrastructure layer targeting the mechanisms of cellular aging. The market is fragmented across supplements, clinics and consumer labels.
Aging is progressive regulatory drift at the cellular level. ChayimTech is built as a two-layer platform.
A chromosome-resolved telomere clock on long-read sequencing — the diagnostic that proves whether any intervention is actually working.
Transient mRNA constructs targeting age-associated pathways — mitochondrial function, stress resilience, repair. Controlled and reversible, not permanent gene editing.
Telomere length is the most-used molecular proxy of cellular aging, but nearly every assay reports a qPCR-derived average — collapsing rich, chromosome-specific biology into a single number.
ultra-short telomeres are enough to push a cell into senescence — yet a mean length averages them away.
Published — not our claim.Three independent, peer-reviewed findings make our approach the obvious next step — we are building the clock that operationalizes them.
It is the single shortest telomere — not the average — that triggers replicative senescence and a DNA-damage response.
Hemann et al., Cell 2001 · Abdallah et al., Nat Cell Biol 2009Average telomere length is, at best, a rough estimate of aging; ultra-short-telomere load predicts senescence far better.
Vaiserman & Krasnienkov, Front. Genet. 2020Oxford Nanopore long-read sequencing now measures chromosome- and allele-specific telomere lengths, reproducibly, at scale.
Sanchez et al., Nat. Commun. 2024 (Telo-seq)Systematic construct design targeting defined aging pathways — a reusable, expandable toolkit rather than one drug.
Every construct judged against quantitative, data-guided readouts — including our own biological-age clock.
Temporary modulation without permanent genomic alteration — controllable and safety-aligned.
ChayimTech Labs sells elite biotech R&D — experimental design, validation and proof-of-concept — to pharma and platform partners, generating revenue and credibility while the therapeutic platform matures.
Our first outreach is to the Applications team at Oxford Nanopore Technologies (LSE: ONT), to evaluate a chromosome-resolved telomere clock on real cohorts — a new cohort-scale application for their platform and external validation for ours.
More than a CRO: founder-level scientific partnership.
Cellular-reprogramming leaders are extraordinarily well funded but capital-intensive and measurement-blind. ChayimTech enters at the earliest layer — quantifying biological age — with a fraction of the capital.
| Company | Approach | Funding / valuation |
|---|---|---|
| Altos Labs | Partial cellular reprogramming | ~$5B raised |
| Retro Biosciences | Reprogramming + autophagy | ~$5B valuation ($1B round) |
| NewLimit | Epigenetic reprogramming | ~$1.62B valuation |
| ChayimTech | Measurement + reversible mRNA modulation | Capital-efficient |
A focused core assembles a vetted crew of senior scientists for each program. The same model powers ChayimTech Labs — world-class R&D scaled to the project, without the fixed overhead of a traditional CRO.
Sets the vision, raises and deploys capital, coordinates regulatory strategy, and assembles the scientific crew behind each program.
Senescence, p53 and cancer cell biology — experimental design and validation.
Cell-screening and assay execution for translational programs.
mRNA molecular design and aging-pathway architecture.
Advisors Levi Shapiro — Founder, mHealth Israel; Managing Partner, Life Science Vision Capital · Dr. Vered Bar — CureResponse · strategic VC partner (Argentina), closing.
We're raising a seed round and opening our first research engagements. Investor materials available on request.
Leave your details and we'll get back to you — for investment, scientific collaboration, or a research program.
For investors, scientific collaborators, and pharma / platform R&D clients.